Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome + 5-FU/LV vs placebo + 5-FU/LV in second-line pancreatic cancer
CTR20191182Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2019
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan liposome in pancreatic adenocarcinoma (PDAC), sponsored by Hengrui Therapeutics. Started Jun 2019; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20191182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191182.